Melittin: a possible regulator of cancer proliferation in preclinical cell culture and animal models

dc.contributor.authorHaque, Shafiul
dc.contributor.authorHussain, Arif
dc.contributor.authorJoshi, Hemant
dc.contributor.authorSharma, Ujjawal
dc.contributor.authorSharma, Bunty
dc.contributor.authorAggarwal, Diwakar
dc.contributor.authorRani, Isha
dc.contributor.authorRamniwas, Seema
dc.contributor.authorGupta, Madhu
dc.contributor.authorTuli, Hardeep Singh
dc.date.accessioned2024-01-21T10:54:19Z
dc.date.accessioned2024-08-14T07:41:03Z
dc.date.available2024-01-21T10:54:19Z
dc.date.available2024-08-14T07:41:03Z
dc.date.issued2023-11-03T00:00:00
dc.description.abstractBackground: Melittin is a water-soluble cationic peptide derived from bee venom that has been thoroughly studied for the cure of different cancers. However, the unwanted interactions of melittin produce hemolytic and cytotoxic effects that hinder their therapeutic applications. To overcome the shortcomings, numerous research groups have adopted different approaches, including conjugation with tumor-targeting proteins, gene therapy, and encapsulation in nanoparticles, to reduce the non-specific cytotoxic effects and potentiate their anti-cancerous activity. Purpose: This article aims to provide mechanistic insights into the chemopreventive activity of melittin and its nanoversion in combination with standard anti-cancer drugs for the treatment of cancer. Methods: We looked over the pertinent research on melittin's chemopreventive properties in online databases such as PubMed and Scopus. Conclusion: In the present article, the anti-cancerous effects of melittin on different cancers have been discussed very nicely, as have their possible mechanisms of action to act against different tumors. Besides, it interacts with different signal molecules that regulate the diverse pathways of cancerous cells, such as cell cycle arrest, apoptosis, metastasis, angiogenesis, and inflammation. We also discussed the recent progress in the synergistic combination of melittin with standard anti-cancer drugs and a nano-formulated version of melittin for targeted delivery to improve its anticancer potential. Graphical abstract: [Figure not available: see fulltext.] � 2023, The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.en_US
dc.identifier.doi10.1007/s00432-023-05458-8
dc.identifier.issn1715216
dc.identifier.urihttps://kr.cup.edu.in/handle/32116/4279
dc.identifier.urlhttps://link.springer.com/10.1007/s00432-023-05458-8
dc.language.isoen_USen_US
dc.publisherSpringer Science and Business Media Deutschland GmbHen_US
dc.subjectChemopreventionen_US
dc.subjectInflammationen_US
dc.subjectMelittinen_US
dc.subjectMetastasisen_US
dc.subjectNanoformulationen_US
dc.titleMelittin: a possible regulator of cancer proliferation in preclinical cell culture and animal modelsen_US
dc.title.journalJournal of Cancer Research and Clinical Oncologyen_US
dc.typeReviewen_US
dc.type.accesstypeClosed Accessen_US

Files